CHRO — Channel Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $7.69m
- $9.36m
Annual cashflow statement for Channel Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.661 | -0.595 | -2.46 | -7.38 | -7.96 |
| Non-Cash Items | 0 | -0.242 | 0.251 | 4.15 | 2.08 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.97 | -0.756 | 0.641 | 2.25 | 0.08 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -3.63 | -1.59 | -1.57 | -0.981 | -5.79 |
| Financing Cash Flow Items | 3.38 | 1.59 | 1.22 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 3.63 | 1.59 | 1.62 | 1.02 | 6.21 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0 | 0 | 0.055 | 0.041 | 0.417 |